Cadila will supply the oncology drug to joint venture partner Hospira. Cadila has now collaborated with Hospira to supply the oncology drug. Cadila was approved to market the generic Taxotere that went off patent last year in November 2010. This has opened ways for other generic companies to take over. The drug taxotere treats breast, lung and other types of cancer and has a market size of $1.2 billion. Taxotere is the registered product of Sanofi-Aventis. Cadila will market the drug to specified markets such as India and latin America. Since there are only two to three players in selling the drug in 2011-12, Cadila aims to take 30 percent of the share in the market. There will be 50 per cent price erosion for 2011-12 and a 40 plus per cent market share for Hospira leading to $53 million sales for Cadila adding to Rs 5.2 in earnings per share.